博瑞医药(688166.SH)：BGM0504片获批在成人超重/肥胖患者中开展临床试验

Core Viewpoint - The announcement highlights that Borui Pharmaceutical's subsidiary has received approval from the National Medical Products Administration to conduct clinical trials for BGM0504 tablets in overweight and obese adults, indicating a significant step in the development of a new treatment for metabolic diseases [1] Group 1: Product Development - BGM0504 is a dual agonist of GLP-1 and GIP receptors, which can activate downstream pathways to control blood sugar, promote weight loss, and treat non-alcoholic fatty liver disease (NASH) [1] - The injectable form of BGM0504 is currently in Phase III clinical trials for type 2 diabetes and weight loss indications in China [1] - As of the date of the announcement, there are no approved oral formulations targeting the same receptors globally, positioning BGM0504 tablets as a potentially unique product in the market [1]